Cancer Research

Microbiome
#Microbiome #National Cancer Institute #National Institutes of Health (NIH) #Oncology #The Francis Crick Institute #vitamin D

Vitamin D boosts ‘good’ bacteria and improves immunity to cancer

Researchers have found that vitamin D encourages the growth of a type of gut bacteria in mice which improves immunity to cancer. The researchers from the Francis Crick Institute, the National Cancer Institute (NCI) of the US National Institutes of Health (NIH) and Aalborg University in… Read More

#Cancer Research #News #Trending News

Bowl of rice bran
#Japan #Nanomedicine / nanotechnology #Oncology #Precision medicine #Tokyo University of Science

Rice bran nanoparticles show promise as targeted cancer therapy

Researchers have discovered that nanoparticles derived from rice bran are both effective and safe for the treatment of cancer. Cancer therapies that employ nanoparticles can specifically target cancer cells, sparing healthy tissue. Recent studies have demonstrated that plant-derived nanoparticles (pdNPs) that have therapeutic effects… Read More

#Cancer Research #Editor's Choice #News

#Antibodies #Antiverse #Artificial intelligence (AI) #Generative AI #Oncology

Advancing antibody cancer therapeutics with AI

Antiverse is an artificial intelligence (AI)-driven company that specialises in antibody design against difficult-to-drug targets, including G-protein coupled receptors (GPCRs) and ion channels. Murat Tunaboylu, Co-founder and CEO of Antiverse, speaks with Megan Thomas about how AI can advance therapeutic antibody design. Megan T: How is Antiverse using AI in… Read More

#Cancer Research #Exclusive Content

Melanoma or skin cancer
#3D imaging #Cancer drug targets #Drug targets #Oncology #Skin cancer #The Institute of Cancer Research

Discovery reveals two potential drug targets against skin cancer

Scientists have discovered how skin cancer cells shapeshift based on their environment – enabling them to spread through the body and cause a metastatic cancer. The discovery of two genes responsible for sensing the environment and adapting cell shape could offer potential new drug targets to… Read More

#Cancer Research #Editor's Choice #News

Cancer cells
#Cancer #Drug discovery #Immunotherapy #Oncology

Optimising the use of immunotherapies to treat cancer 

Sharad Adekar, Medical Chair Lead and Currien MacDonald, Medical Chair Director at WCG, discuss the risks and benefits of using immunotherapies to treat cancer.  In the last decade, a paradigm shift has occurred in the landscape of cancer treatment1. Supported by current advances in understanding of the mechanism and pathways… Read More

#Cancer Research #Exclusive Content

Prostate cancer cells
#mRNA #Nutcracker Therapeutics #Oncology #Prostate cancer #T cell activation

mRNA prostate cancer drug successfully engaged CD3 T cells

Nutcracker Therapeutics’ prostate cancer mRNA drug candidate NTX-470 successfully engaged CD3 T cells, while retaining low bystander activity and reduced off-tumour binding, according to data presented at the 2024 AACR Annual Meeting. There are limited treatment options for the 10-20% of prostate cancer patients who develop… Read More

#Cancer Research #News

#Antibodies #Cancer research #Oncology #Phase III trial #Therapeutic Antibodies

Improving the standard of care: Inside the DUO-E trial

Professor Shannon Westin is principal investigator of the DUO-E trial, here she speaks to DDW’s Megan Thomas about why the standard of care needs improving and the impact of therapeutic antibodies such as durvalumab. The DUO-E trial is a three-arm, randomised, double-blind, placebo-controlled, multicentre Phase III trial assessing the combination… Read More

#Cancer Research #Exclusive Content

#Career #Infectious diseases #Interview #Kling Biotherapeutics #Meet the Researcher

Meet the researcher: Stefano Gullà, Kling Biotherapeutics

DDW’s Megan Thomas speaks to Stefano Gullà, Chief Scientific Officer at Kling Biotherapeutics.   MT: Where do you work, and can you tell us what you’re working on at the moment?  SG: I am the Chief Scientific Officer at Kling Biotherapeutics. Together with my colleagues, I am tackling what is… Read More

#Cancer Research #Exclusive Content

San Diego
#AACR #Cancer research #Events #Oncology

News from AACR 2024: Tuesday’s highlights

Today, National Cancer Institute leaders discussed cancer breakthroughs and the importance of securing support from lawmakers for the NCI and National Institutes of Health in the session ‘The Cancer Moonshot: Opportunities to Fulfill the Vision of the National Cancer Plan – Dedicated to the Memory of Sen. Dianne… Read More

#Cancer Research #News #Trending News

San Diego
#AACR #Cancer research #Events #Oncology

News from AACR 2024: Monday’s highlights

A round-up of the latest news from the American Association of Cancer Research (AACR) Annual Meeting. Symposiums UCLA: Dr Zev Wainberg, Co-Director of the UCLA Health GI Oncology Program, presented results from pilot study led by UCLA Health Jonsson Comprehensive Cancer Center investigators, which suggests that for… Read More

#Cancer Research #News #Trending News

#Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology #University of California

Genetically engineered dendritic cells enhance lung cancer therapy

A study by researchers at the UCLA Health Jonsson Comprehensive Cancer Center in the US suggests that injecting engineered dendritic cells directly into cancerous lung tumours can help promote a stronger immune response. When tested in mice with non-small cell lung cancer (NSCLC), the team discovered… Read More

#Cancer Research #News

San Diego
#AACR #Cancer research #Events #Oncology

News from AACR 2024: Sunday’s highlights

The American Association of Cancer Research (AACR) Annual Meeting launched on Sunday 7 April in San Diego with an Opening Plenary Session showcasing cutting-edge technological advances opening new frontiers in cancer science. The session ‘Inspiring Science, Fueling Progress, Revolutionizing Care’ featured a distinguished panel of cancer… Read More

#Cancer Research #News #Trending News

Cancer Abnormal Cells Nucleus Genetic Division Infection Microscope
#Cancer #Cancer research #Curve Therapeutics #Therapeutics

Research supports HIF inhibition as a therapeutic approach for cancer 

Curve Therapeutics’ CSO Ali Tavassoli has published an article in the Journal of the American Chemical Society (JACS) which highlights the potential of HIF inhibition as a therapeutic approach for cancers. The paper is titled ‘Identification and Development of Cyclic Peptide Inhibitors of Hypoxia Inducible Factors (HIF) 1 and… Read More

#Cancer Research #News

Antibodies
#Bio-Rad Laboratories #Cancer research #Circulating tumour cell enumeration #Tumours

Validated antibodies for rare cell and circulating tumour cell enumeration 

Bio-Rad Laboratories has launched validated antibodies for rare cell and circulating tumour cell (CTC) enumeration for use with Bio-Rad’s Celselect Slides Enumeration Stain Kits.  The antibodies are specific to CTC surface markers to enable the sensitive and specific identification of target cell populations, enhancing the study of… Read More

#Cancer Research #News